Get the Stockscreener App
70.14
1.48%
0.66
Belite Bio Inc Adr stock is traded at $70.14, with a volume of 7,633.
It is up +1.48% in the last 24 hours and up +24.63% over the past month.
Belite Bio Inc is a clinical-stage biopharmaceutical drug development company focused on novel therapeutics targeting untreatable eye diseases involving retinal degeneration such as atrophic age-related macular degeneration and autosomal recessive Stargardt disease or STGD1, both of which progressively lead to permanent blindness, and metabolic diseases such as non-alcoholic fatty liver disease, or NAFLD, nonalcoholic steatohepatitis, or NASH, type 2 diabetes, or T2D, and gout.
See More
Previous Close:
$69.48
Open:
$70.11
24h Volume:
7,633
Relative Volume:
0.17
Market Cap:
$2.24B
Revenue:
-
Net Income/Loss:
$-32.61M
P/E Ratio:
-59.73
EPS:
-1.1742
Net Cash Flow:
-
1W Performance:
+15.47%
1M Performance:
+24.63%
6M Performance:
+44.42%
1Y Performance:
+85.44%
1-Day Range:
$69.40
$70.99
1-Week Range:
$61.50
$70.99
52-Week Range:
$31.00
$86.53
Belite Bio Inc Adr Stock (BLTE) Company Profile
Compare BLTE with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
BLTE
Belite Bio Inc Adr
|
70.50 | 2.24B | 0 | -32.61M | 0 | -1.1742 |
|
VRTX
Vertex Pharmaceuticals Inc
|
501.29 | 130.96B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
683.26 | 75.53B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
579.20 | 35.07B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
241.17 | 31.72B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
249.50 | 26.76B | 3.32B | -860.46M | -1.04B | -8.32 |
Belite Bio Inc Adr Stock (BLTE) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Dec-14-23 | Initiated | Maxim Group | Buy |
| Jul-28-23 | Initiated | Cantor Fitzgerald | Overweight |
| Jul-26-23 | Initiated | SVB Securities | Outperform |
| Aug-01-22 | Initiated | H.C. Wainwright | Buy |
| Jul-01-22 | Initiated | The Benchmark Company | Buy |
Belite Bio Inc Adr Stock (BLTE) Latest News
Dry AMD Market Expected to rise, 2034 | Alkeus Pharmaceuticals, Belite Bio, Aviceda Therapeutics, Johnson & Johnson Innovative Medicine, Allegro Ophthalmics, Lineage Cell Therapeutics - The Globe and Mail
Belite Bio to Host Webcast on March 17, 2025, to Discuss Fourth Quarter and Full Year 2024 ... - The Bakersfield Californian
Biotech Pioneer Belite Bio Unveils Q4 and 2024 Performance: Key Retinal Disease Updates Coming March 17 - StockTitan
Is Meta Platforms Stock a Buy, Sell, or Hold Ahead of Llama 4 Launch? - The Globe and Mail
Parkland Reports Fourth Quarter and Year-End 2024 Results; Initiates Review of Strategic Alternatives - The Globe and Mail
Darwin CX Expands Internationally, Aiming to Tackle Global Publishing Challenges with Locally Tailored Solutions - The Globe and Mail
Can Belite Bio's Retinal Disease Treatments Impress Investors at Upcoming Leerink Conference? - StockTitan
2 Large-Cap Stocks with Exciting Potential and 1 to Avoid - The Globe and Mail
Belite Bio (NASDAQ:BLTE) Shares Gap UpShould You Buy? - MarketBeat
Promising Phase 3 Results for Belite Bio’s Tinlarebant in Stargardt Disease Boost Buy Rating - TipRanks
Belite Bio’s Phase 3 Trial for Stargardt Disease Drug Advances - TipRanks
Can Belite Bio's Tinlarebant Become First Treatment for Stargardt Disease? Phase 3 Data Shows Promise - StockTitan
Belite Bio (NASDAQ:BLTE) Sees Unusually-High Trading VolumeTime to Buy? - MarketBeat
Belite Bio, Inc (NASDAQ:BLTE) Short Interest Down 9.2% in January - MarketBeat
Belite Bio (NASDAQ:BLTE) Stock Price Up 7.8%Should You Buy? - MarketBeat
Belite Bio (NASDAQ:BLTE) Shares Down 4.7%Time to Sell? - MarketBeat
Advisors Preferred LLC Purchases New Shares in Belite Bio, Inc (NASDAQ:BLTE) - Armenian Reporter
Why Are Cloudflare (NET) Shares Soaring Today - The Globe and Mail
Belite Bio Announces $15 Million Direct Offering to Enhance Financial Position - TipRanks
BLTEBelite Bio, Inc Latest Stock News & Market Updates - StockTitan
Sangoma Announces Second Quarter Fiscal 2025 Results - The Globe and Mail
Why Oklo Stock Jumped 96% in January - The Globe and Mail
Belite Bio Raises Fresh Capital: $30M Total Potential as Clinical Programs Advance - StockTitan
Belite Bio Announces Registered Direct Offering of $15 Million - GlobeNewswire Inc.
Flow Beverage Corp. Adds José Bautista as Strategic Advisor and Closes Second Tranche of Private Placement of Convertible Debenture Units - The Globe and Mail
Why Dominion Energy Stock Was Falling Today - The Globe and Mail
Leerink Partnrs Increases Earnings Estimates for Belite Bio - MarketBeat
Belite Bio, Inc (NASDAQ:BLTE) Stake Increased by JPMorgan Chase & Co. - MarketBeat
Stargardt Disease Market Growth to Accelerate in Forecast Period (2024-2034) | estimates DelveInsight - openPR
Where Will Nvidia Stock Be in 3 Years? - The Globe and Mail
Apple Stock Is Off Its Recent Highs, But Is It Poised to Rise Again? - The Globe and Mail
Short Interest in Belite Bio, Inc (NASDAQ:BLTE) Decreases By 60.3% - MarketBeat
Bitcoin: Buy the Dip? - The Globe and Mail
JPMorgan Chase & Co. Grows Stock Holdings in Belite Bio, Inc (NASDAQ:BLTE) - Defense World
Is Coffee Moving to Even Higher Highs? - The Globe and Mail
Charter (CHTR) Reports Q4: Everything You Need To Know Ahead Of Earnings - The Globe and Mail
Are These Renewable Energy Stocks in Trouble, or Are They Ultra-Cheap Buys? - The Globe and Mail
The Ultimate Growth Stock to Buy With $1,000 Right Now - The Globe and Mail
Rigetti CEO Responds to Jensen Huang and Mark Zuckerberg on the Future of Quantum Computing - The Globe and Mail
Avoid the Trap: 3 High-yield Dividend Stocks With Safe Payouts - The Globe and Mail
2 Artificial Intelligence Stocks You Can Buy and Hold for the Next Decade - The Globe and Mail
4 Soaring Stocks I'd Buy Now With No Hesitation - The Globe and Mail
Analysts Predict 1,250% Upside for This ‘Strong Buy’ Quantum Computing Stock in 2025... But Investors Should Stay Away - The Globe and Mail
XFRA : ICFFRENDE DER HANDELSUNTERBRECHUNG IN DIVERSEN AKTIENTEIL 2 () - Aktiencheck
Belite Bio (NASDAQ:BLTE) Shares Gap Up After Analyst Upgrade - Defense World
Belite Bio (NASDAQ:BLTE) Shares Gap Up Following Analyst Upgrade - MarketBeat
Benchmark Issues Positive Forecast for Belite Bio (NASDAQ:BLTE) Stock Price - Defense World
Benchmark Boosts Belite Bio (NASDAQ:BLTE) Price Target to $79.00 - MarketBeat
Belite Bio Inc Adr Stock (BLTE) Financials Data
Revenue
Net Income
Cash Flow
EPS
5.68%
0.28%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):